TAB3: A Potential Drug Target and Biomarker for Ovarian Cancer

Target Name: TAB3

NCBI ID: G257397

TAB3

TAB3: A Potential Drug Target and Biomarker for Ovarian Cancer

Introduction

Ovarian cancer is a leading cause of cancer death in women, affecting an estimated 21,123 new cases and 12,290 deaths in the United States alone in 2020. Despite advances in treatment, the survival rate for ovarian cancer remains largely the same, highlighting the need for new treatments and biomarkers. TAB3 (Triazactone A) is a drug that has been shown to have potential in targeting ovarian cancer cells. In this article, we will explore the potential of TAB3 as a drug target and biomarker for ovarian cancer.

Targeting Ovarian Cancer Cells

TAB3 is a compound extracted from the tubulin acetylated microtubules of the mitotic spindle. It has been shown to inhibit the formation of new microtubules, leading to the disruption of the spindle network and the failure of cell division. This disruption of cell division can result in the inhibition of the growth and spread of ovarian cancer cells.

In addition to its effects on cell division, TAB3 has been shown to induce apoptosis (programmed cell death) in ovarian cancer cells. Apoptosis is a natural response of cancer cells to DNA damage and is associated with the development of cancer. The induction of apoptosis by TAB3 may be due to its ability to disrupt the formation of new microtubules, which can lead to the formation of tangles and other disruptions in the cell's cytoskeleton.

Potential Drug Target

The inhibition of microtubule formation by TAB3 makes it a potential drug target for ovarian cancer. Microtubules are the basic structures that form the spindle network in eukaryotic cells, and TAB3 interferes with the assembly of the spindle network by inhibiting the formation of microtubules, leading to The inhibition of cell mitosis provides a theoretical basis for TAB3 as a therapeutic target for ovarian cancer.

biomarker

TAB3 can also serve as a biomarker for ovarian cancer. Some studies have shown that ovarian cancer cell lines treated with TAB3 produce alpha-tubulin, a protein that should not be present normally. The production of these 伪-tubulin suggests that TAB3 may interfere with spindle network formation in ovarian cancer cells, leading to the inhibition of cell mitosis. In addition, TAB3 can also induce apoptosis in ovarian cancer cells, which is a way for ovarian cancer cells to self-destruct. TAB3-induced apoptosis can be monitored through the S phase of the cell cycle and therefore can serve as a biomarker for ovarian cancer.

Conclusion

TAB3 is a potential drug target and biomarker for the treatment of ovarian cancer. Its mechanism of action is to interfere with the division of cancer cells by inhibiting the formation of spindle networks, and can also induce apoptosis of cancer cells. These effects suggest that TAB3 could become an effective new drug for the treatment of ovarian cancer. Future studies can further explore the role of TAB3 in the treatment of ovarian cancer and whether it can become a reliable biomarker.

Protein Name: TGF-beta Activated Kinase 1 (MAP3K7) Binding Protein 3

Functions: Adapter required to activate the JNK and NF-kappa-B signaling pathways through the specific recognition of 'Lys-63'-linked polyubiquitin chains by its RanBP2-type zinc finger (NZF) (PubMed:14633987, PubMed:14766965, PubMed:15327770, PubMed:22158122). Acts as an adapter linking MAP3K7/TAK1 and TRAF6 to 'Lys-63'-linked polyubiquitin chains (PubMed:14633987, PubMed:14766965, PubMed:15327770, PubMed:22158122, PubMed:36593296). The RanBP2-type zinc finger (NZF) specifically recognizes Lys-63'-linked polyubiquitin chains unanchored or anchored to the substrate proteins such as RIPK1/RIP1: this acts as a scaffold to organize a large signaling complex to promote autophosphorylation of MAP3K7/TAK1, and subsequent activation of I-kappa-B-kinase (IKK) core complex by MAP3K7/TAK1 (PubMed:15327770, PubMed:22158122)

The "TAB3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAB3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets